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1. INTRODUCTION {#humu23890-sec-0010}
===============

Inherited retinal diseases (IRDs) are clinically and genetically heterogeneous conditions (Berger, Kloeckener‐Gruissem, & Neidhardt, [2010](#humu23890-bib-0005){ref-type="ref"}; Sullivan & Daiger, [1996](#humu23890-bib-0042){ref-type="ref"}), which makes it a great challenge for clinicians to come to a genetic diagnosis in affected individuals. However, by defining the genetic cause, the genetic risk of the disease for other family members can be assessed and it provides essential prognostic information for affected family members and possible therapeutic approaches. More knowledge of genetic variability in a gene will also provide better insight and understanding of the disease mechanism (Carss et al., [2017](#humu23890-bib-0009){ref-type="ref"}; Ellingford et al., [2015](#humu23890-bib-0018){ref-type="ref"}).

The rise of next‐generation sequencing technology has drastically changed the opportunities in obtaining a genetic diagnosis in affected individuals (Neveling et al., [2012](#humu23890-bib-0030){ref-type="ref"}; Vaz‐Drago, Custódio, & Carmo‐Fonseca, [2017](#humu23890-bib-0045){ref-type="ref"}). Using these techniques, hundreds of thousands of single‐nucleotide (nt) variants are detected in each individual. However, in many instances, the functional significance of variants remains unclear. Several in silico tools predict the putative effect of missense and splice variants. The latter variants can be experimentally assessed for their pathogenicity by performing in vitro midigene splice assays (Sangermano et al., [2018](#humu23890-bib-0036){ref-type="ref"}).

Stargardt disease 1 (STGD1; MIM\# 600110) is the most common inherited macular disease. It is characterized by bilateral progressive loss of central vision, color vision defect, photophobia, and importantly, delayed dark adaptation and fundus imaging point to accumulation of lipofuscin (Fishman, Farbman, & Alexander, [1991](#humu23890-bib-0021){ref-type="ref"}; Stargardt, [1909](#humu23890-bib-0041){ref-type="ref"}). STGD1 is an autosomal recessive disease caused by pathogenic variants in the ATP‐binding cassette subfamily A member 4 (*ABCA4*) gene (MIM\# 601691; NM_000350.2; Allikmets et al., [1997](#humu23890-bib-0003){ref-type="ref"}). The protein is comprised of two tandem halves, each of which consists of a nt‐binding domain, a cytoplasmic domain, and a transmembrane domain, followed by a large extracellular segment (Bungert, Molday, & Molday, [2001](#humu23890-bib-0007){ref-type="ref"}). *ABCA4* is a 128 kb gene containing 50 exons that encodes a polypeptide of 2,273 amino acids and is located in the rod and cone photoreceptor cells, as well as the retinal pigment epithelium (Ahn, Wong, & Molday, [2000](#humu23890-bib-0001){ref-type="ref"}; Lenis et al., [2018](#humu23890-bib-0026){ref-type="ref"}; Sun, Molday, & Nathans, [1999](#humu23890-bib-0043){ref-type="ref"}). One or both copies of this gene were found to be mutated in the majority of patients with STGD1 (Zernant et al., [2014](#humu23890-bib-0050){ref-type="ref"}), in 30% of patients with cone‐rod dystrophy (Cremers et al., [1998](#humu23890-bib-0014){ref-type="ref"}; Maugeri et al., [2000](#humu23890-bib-0028){ref-type="ref"}), and in approximately 5% of individuals with pan‐retinal dystrophy or a phenotype resembling retinitis pigmentosa (Cremers et al., [1998](#humu23890-bib-0014){ref-type="ref"}).

The *ABCA4* gene carries many pathogenic noncanonical splice site (NCSS) variants. A comprehensive study on all *ABCA4* variants published up to 2016 showed a total of 5,962 likely causal variants or alleles in *ABCA4* of which 13.6% (809/5,962) are located in NCSS (Cornelis et al., [2017](#humu23890-bib-0013){ref-type="ref"}). These NCSS variants are located at the first and last three nucleotides of an exon as well as the −3 to −14nts from the acceptor site, and +3 to +6 from the donor site. Besides NCSS variants, many pathogenic variants were observed in canonical sequences at the AG‐acceptor (−1 and −2) and GT‐donor (+1 and +2) nucleotides. The functional consequences of many NCSS variants in *ABCA4* were revealed using in vitro minigene and midigene splice assays in human embryonic kidney 293T (HEK293T) cells (Sangermano et al., [2018](#humu23890-bib-0036){ref-type="ref"}; Schulz et al., [2017](#humu23890-bib-0037){ref-type="ref"}).

Until recently, a single pathogenic variant was identified in approximately 25% of STGD1 cases worldwide (Zernant et al., [2017](#humu23890-bib-0049){ref-type="ref"}, [2014](#humu23890-bib-0050){ref-type="ref"}). Approximately 40% of these cases (\~10% of all STGD1 cases), many of whom showing late‐onset STGD1, were explained by the frequent coding variant c.5603A\>T (p.Asn1868Ile) with an allele frequency of 0.07 in most control populations. This variant generally was found in *trans* with severe *ABCA4* variants (Runhart et al., [2018](#humu23890-bib-0033){ref-type="ref"}; Zernant et al., [2017](#humu23890-bib-0049){ref-type="ref"}). Another 40% of monoallelic STGD1 probands (10% of all STGD1 cases) carried deep‐intronic variants in their second alleles (Bauwens et al., [2019](#humu23890-bib-0004){ref-type="ref"}; Braun et al., [2013](#humu23890-bib-0006){ref-type="ref"}; Sangermano et al., [2019](#humu23890-bib-0035){ref-type="ref"}; Zernant et al., [2014](#humu23890-bib-0050){ref-type="ref"}). The functional consequences of many of these variants only came to light when performing in vitro splice assays (Bauwens et al., [2019](#humu23890-bib-0004){ref-type="ref"}; Sangermano et al., [2019](#humu23890-bib-0035){ref-type="ref"}) or by reverse transcription‐polymerase chain reaction (RT‐PCR) analysis of photoreceptor progenitor cells differentiated from patient‐derived induced pluripotent stem cells (Albert et al., [2018](#humu23890-bib-0002){ref-type="ref"}; Sangermano et al., [2016](#humu23890-bib-0034){ref-type="ref"}).

To expand the knowledge of the consequences of NCSS and deep‐intronic variants in *ABCA4*, we studied reported and unpublished NCSS, as well as reported deep‐intronic variants in *ABCA4* employing midigene‐based splice assays. This study contributes to a deeper understanding of alternative splicing through the activation of cryptic splice sites and the presence of exonic splice enhancers (ESEs) or exonic splice silencers (ESSs) and provides evidence for the pathogenicity of 12 splicing variants, thereby significantly expanding our knowledge of the effects of putative splice defects.

2. MATERIALS AND METHODS {#humu23890-sec-0020}
========================

2.1. Editorial policies and ethical considerations {#humu23890-sec-0030}
--------------------------------------------------

The study adhered to the tenets of the Declaration of Helsinki and was approved by the local ethics committees of each participating center. Written informed consent was obtained from patients before inclusion in the study.

2.2. Clinical studies {#humu23890-sec-0040}
---------------------

The 12 probands carried pathogenic *ABCA4* variants (Table S1) and were diagnosed with macular dystrophies or cone‐rod dystrophy (Tables S2 and S3). Medical records of each patient were reviewed for clinical examination including the age of onset, visual acuity, fundus photography, and electroretinogram, where available.

2.3. Selection of NCSS and deep‐intronic *ABCA4* variants {#humu23890-sec-0050}
---------------------------------------------------------

Variants were selected for in vitro analysis when they adhered to the following criteria: (a) NCSS and "near exon aberrant RNA" (NEAR) splice variants were predicted to result in a reduction of at least 2% of the relative strength in at least two of five different splice site prediction algorithms i.e. Splice Site Finder‐like (SSFL), MaxEntScan, NNSPLICE, GeneSplicer, and human splicing finder (HSF) (Desmet et al., [2009](#humu23890-bib-0016){ref-type="ref"}; Pertea et al., [2001](#humu23890-bib-0031){ref-type="ref"}; Reese et al., [1997](#humu23890-bib-0032){ref-type="ref"}; Shapiro & Senapathy, [1987](#humu23890-bib-0038){ref-type="ref"}; Yeo & Burge, [2004](#humu23890-bib-0048){ref-type="ref"}). Moreover, variants were selected when nearby (up to 300 base pairs \[bps\]) a cryptic splice site was strengthened or created.

Deep‐intronic variants were included if a mutant cryptic splice site was predicted by at least two out of five algorithms with ≥75% score in the presence of an already existing other splice site within 300 nts, which together could result in the formation of a pseudoexon (PE) (Sangermano et al., [2019](#humu23890-bib-0035){ref-type="ref"}). As it has been shown that ESEs and ESSs have a significant effect on the splicing process in human cells we assessed ESEs through ESEfinder, an in silico prediction tool integrated with Alamut® version 2.10 (Cartegni, Chew, & Krainer, [2002](#humu23890-bib-0010){ref-type="ref"}; Fairbrother & Chasin, [2000](#humu23890-bib-0019){ref-type="ref"}). ESEfinder determines the presence of five different ESE elements, that is SF2/ASF, SF2/ASF (immunoglobulin M‐BRCA1), SC35, SRp40, and SRp55 (Cartegni, Wang, Zhu, Zhang, & Krainer, [2003](#humu23890-bib-0011){ref-type="ref"}; Smith et al., [2006](#humu23890-bib-0040){ref-type="ref"}). Moreover, suggested pathogenic variants adhered to the selection criteria when differences could be observed in predicted ESEs or ESSs between wild‐type (WT) and mutant sequences. ESSs were assessed through algorithms incorporated in HSF as introduced by Wang et al. ([2004](#humu23890-bib-0046){ref-type="ref"}) and Sironi et al. ([2004](#humu23890-bib-0039){ref-type="ref"}).

Nineteen variants were selected to be assessed by a midigene splice assays. All in silico splice site prediction scores of the variants investigated in this study are provided in Table S4. Of these, 16 variants were previously reported (Bauwens et al., [2019](#humu23890-bib-0004){ref-type="ref"}; Cornelis et al., [2017](#humu23890-bib-0013){ref-type="ref"}; Fujinami et al., [2013](#humu23890-bib-0022){ref-type="ref"}; Tayebi et al., [2019](#humu23890-bib-0044){ref-type="ref"}; Zernant et al., [2017](#humu23890-bib-0049){ref-type="ref"}, [2014](#humu23890-bib-0050){ref-type="ref"}; Zhang, Arias, Ke, & Chasin, [2009](#humu23890-bib-0051){ref-type="ref"}), we also assessed in‐house data based on molecular inversion probes‐based sequence analysis of 108 inherited retina‐disease associated genes in an approximately 5,000 probands (S. R. and F. P. M. C., unpublished data). The latter analysis led to the inclusion of c.1937+5G\>A, c.5715−5T\>G, and c.6147G\>A, as these fulfilled the criteria described above.

2.4. Generation of *ABCA4* WT and mutant midigenes {#humu23890-sec-0060}
--------------------------------------------------

Previously, we generated a library of 31 overlapping WT midigenes (BA1--BA31; Sangermano et al., [2018](#humu23890-bib-0036){ref-type="ref"}) (Khan et al., [2019](#humu23890-bib-0024){ref-type="ref"}). Through Gateway cloning and subsequent site‐directed mutagenesis, mutant constructs were generated for all 19 variants investigated in this study (Figure [1](#humu23890-fig-0001){ref-type="fig"}). Subsequently, WT and mutant constructs were independently transfected in HEK293T cells, assessed through RT‐PCR, gel analysis, and followed by Sanger sequencing of the observed fragments. When a multitude of products was observed after gel electrophoresis, they were quantified using Fiji software, as previously described (Sangermano et al., [2018](#humu23890-bib-0036){ref-type="ref"}). In addition, for the c.5715−5T\>G variant, all observed fragments were cloned via the pGEM‐T Easy Vector System I (Promega, Madison, WI) according to the manufacturer\'s protocol and analyzed by Sanger sequencing. All mutagenesis, exonic primers, and quantification measurements are available in Tables S5--S7.

![Schematic representation of mutant midigene splice constructs of *ABCA4* and corresponding locations of the NCSS and deep‐intronic variants tested. The exons are represented as black rectangles. BA depicts the BAC‐derived clones used that were previously described (Sangermano et al., [2018](#humu23890-bib-0036){ref-type="ref"}). The BA11 and BA15 variants each were introduced separately into the WT constructs. *ABCA4*, ATP‐binding cassette subfamily A member 4; BAC, bacterial artificial chromosome; NCSS, noncanonical splice site; WT, wild‐type](HUMU-40-2365-g001){#humu23890-fig-0001}

3. RESULTS {#humu23890-sec-0070}
==========

3.1. Splicing effect of NCSS variants in *ABCA4* {#humu23890-sec-0080}
------------------------------------------------

The nine NCSS variants experimentally assessed with their observed effect on splicing are listed in Table [1](#humu23890-tbl-0001){ref-type="table"}. Of all variants, only two were observed in the "control" population database gnomAD (c.161G\>A, allele frequency: 0.00003608; c.3608−7G\>A, allele frequency: 0.000004087). Four of the selected variants (c.161G\>A, c.4667G\>A, c.6147G\>A, and c.6385A\>G) were in the coding regions of *ABCA4*, whereas the remaining NCSS variants were located in introns. Eight of the nine NCSS variants led to partial or entire exon skipping, while only c.3608−7G\>A did not show an effect on splicing. The c.1937+5G\>A, c.2161−8G\>A, and c.4667G\>A variants led to partial in‐frame deletions of *ABCA4* exons. The c.6385A\>G variant caused an open reading frame disruption by a 47‐nt deletion of exon 46 due to the use of a cryptic splice donor site (SDS) at position c.6340 in the exon (Figure [2](#humu23890-fig-0002){ref-type="fig-group"}). The other five NCSS variants caused frameshifts and led to predicted truncated proteins (Table [1](#humu23890-tbl-0001){ref-type="table"}).

###### 

In vitro assessed NCSS variants and the observed RNA and predicted protein effects

  DNA variant    RNA effect                                                          Protein effect                  Splice defect             Variant effect
  -------------- ------------------------------------------------------------------- ------------------------------- ------------------------- ---------------------------------------------------------
  c.161G\>A      r.\[161_302del,=\][^b^](#humu23890-tbl1-note-0004){ref-type="fn"}   p.\[Cys54Serfs\*14,Cys54Tyr\]   Exon 3 skipping           Moderate[^a^](#humu23890-tbl1-note-0003){ref-type="fn"}
  c.1937+5G\>A   r.1806_1937del                                                      p.(Tyr603_Ser646del)            132‐nt exon 13 deletion   Severe
  c.2161−8G\>A   r.2161_2382del                                                      p.(His721_Val794)               Exon 15 skipping          Severe
  c.3608−7G\>A   r.=                                                                 p.(=)                           None                      N.A.
  c.4667G\>A     r.4635_4667del                                                      p.(Ser1545_Gln1555del)          Exon 32 skipping          Severe
  c.5018+5G\>A   r.4849_5018del                                                      p.(Val1617Alafs\*113)           Exon 35 skipping          Severe
  c.5715−5T\>G   r.5461_5714delins5715‐4_5715‐1                                      p.(Thr1821Serfs\*34)            Exon 39/40 skipping       Severe
  c.6147G\>A     r.6006_6147del                                                      p.(Ser2002Argfs\*11)            Exon 44 skipping          Severe
  c.6385A\>G     r.6340_6386del                                                      p.(Val2114Hisfs\*4)             47‐nt exon 46 deletion    Severe

*Note:* The RNA and protein effect annotations show the most abundant product followed by the less abundant RNA product observed.

Abbreviations: N.A., not applicable; NCSS, noncanonical splice site.

The splice defect is classified as moderate. However, the missense variant Cys54Tyr was proposed earlier to be considered a severe variant in Stargardt cases.

The equal sign depicts the presence of​​​​​ \>15% WT RNAs.

John Wiley & Sons, Ltd.

###### 

Overview of splice defects for nine NCSS variants. Exon 5 *RHO* RT‐PCR was used as a control for transfection efficiency. The chromatogram presents the nucleotides identified in the mutant midigene construct. (a) Exon 3 showed weak natural exon skipping in the WT construct, which is significantly increased for the c.161G\>A mutant. (b) The recruitment of a cryptic SDS in exon 13 at position c.1806 resulted in a 132‐nt deletion. (c) The c.2161−8G\>A mutant construct showed full exon 15 skipping. Note that exon 15 also shows natural exon skipping. (d) c.3608−7G\>A did not result in a splice defect. (e, f) Variants c.4667G\>A and c.5018+5G\>A led to complete exon 32 and 35 skipping, respectively. (g) RT‐PCR for the c.5715−5T\>G mutant construct showed a complex splicing pattern. Exons 39 and 40 are partially skipped in the WT messenger RNA (mRNA); c.5715−5T\>G induced exon 39/40 skipping. This variant also created a new splice acceptor site (SAS) upstream of exon 41 which led to the insertion of four nucleotides into the mature mRNA. (h) c.6147G\>A caused complete exon 44 skipping. (i) The use of a cryptic SDS in exon 46 caused the 47‐nt exon deletion. bp, base pair; HSF, human splicing finder; int, intron; NCSS, noncanonical splice site; nt, nucleotide; RT‐PCR, reverse transcription‐polymerase chain reaction; SDS, splice donor site; WT, wild‐type
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![Overview of splice defects for three deep‐intronic variants and one near exon variant. All WT and mutant midigenes were transfected in HEK293T cells and their splicing effects were identified by RT‐PCR. The exon 5 *RHO* RT‐PCR was used as a control for transfection efficiency. The chromatograms present the nucleotides identified in the mutant midigene construct. (a) Variant c.1938−619A\>G strengthened a cryptic SDS and surprisingly resulted in two independent PE insertions. Fragment 1--2 consists of a fused fragment of two PEs encompassing 134 and 174 nt (PE1--2). PE1 (134 nt) extends from c.1937+396 to c.1937+529 and the boundaries of PE2 (174‐nt) are c.1938−797 and c.1938−624. Fragment 2 contains the second PE of 174‐nt (PE2) only. (b) Variant c.2919−826T\>A strengthened a cryptic SDS and led to a 133‐nt PE. (c) Variant c.3050+370C\>T created a new canonical SDS which resulted in a 105‐nt PE insertion. (d) The NEAR splicing variant c.4352+61G\>A enhanced a cryptic SDS\'s HSF score and elongated exon 29 with 57 nt in 84% percent of the mRNA. bp, base pair; HEK293T, human embryonic kidney 293T; HSF, human splicing factor; mRNA, messenger RNA; NEAR, near exon aberrant RNA; nt, nucleotide; PE, pseudoexon; RT‐PCR, reverse transcription‐polymerase chain reaction; SDS, splice donor site; SSFL, SpliceSiteFinder‐like; WT, wild‐type](HUMU-40-2365-g004){#humu23890-fig-0003}

Variant c.5715−5T\>G, located five nucleotides upstream of exon 41, showed a complex defect in splicing compared with the WT product. Among the different fragments, we observed exon 39 skipping as well as exon 39/40 skipping. The most prominent mutant messenger RNA (mRNA) contained a 4‐nt insertion of the exon 41 splice acceptor site (SAS) along with exon 39/40 skipping. We did not observe any mRNA with only exon 40 skipping.

3.2. Splicing effect of deep‐intronic variants {#humu23890-sec-0090}
----------------------------------------------

The 10 NEAR and deep‐intronic variants with their observed effect on splicing from this study are presented in Table [2](#humu23890-tbl-0002){ref-type="table"}. None of these variants was observed in gnomAD, indicating that they are very rare. Four showed a splicing defect, while the other six variants did not show any effect on splicing (Figure S1). Of the four variants that did show a splice defect, c.1938−619A\>G, c.2919−826T\>A, and c.3050+370C\>T created a PE in the mature mRNAs, leading to a frameshift and a subsequent predicted truncated protein. The NEAR splicing variant c.4352+61G\>A elongated the *ABCA4* mRNA downstream of exon 29 by 57 nts, resulting in a premature stop codon, likely due to an increased cryptic SDS score according to five prediction algorithms, even though there is an inactivation of several ESE protein binding motifs, such as SC35 and SF2/ASF (Figure [3](#humu23890-fig-0003){ref-type="fig"}).

###### 

In vitro assessed near exon and deep‐intronic variants and the observed RNA and predicted protein effects

  DNA variant           RNA effect                                                                                Protein effect                                                          Splice defect              Variant effect
  --------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------- -------------------------- ----------------
  c.768+358C\>T         r.=                                                                                       p.(=)                                                                   None                       N.A.
  c.769−1778T\>C        r.=                                                                                       p.(=)                                                                   None                       N.A.
  c.1938−619A\>G        r.\[1937_1938ins\[1937+396_1937+529;1938‐797_1938‐624\],1937_1938ins1938‐797_1938‐624\]   p.\[Phe647Alafs\*22,Phe647Serfs\*22\]                                   174‐nt PE and 308‐nt PE    Severe
  c.2160+584A\>G        r.=                                                                                       p.(=)                                                                   None                       N.A.
  c.2919−826T\>A        r.\[2918_2919ins2919--957_2919--825,=\][^a^](#humu23890-tbl2-note-0003){ref-type="fn"}    p.\[Leu973Phefs\*1,=\][^a^](#humu23890-tbl2-note-0003){ref-type="fn"}   133‐nt PE                  Severe
  c.3050+370C\>T        r.3050_3051ins3050+164_3050+368                                                           p.(Leu1018Glufs\*4)                                                     205‐nt PE                  Severe
  c.4352+61G\>A         r.\[4352_4353ins4352+1_4352+57,=\][^a^](#humu23890-tbl2-note-0003){ref-type="fn"}         p.\[Glu1452\*,=\][^a^](#humu23890-tbl2-note-0003){ref-type="fn"}        57‐nt exon 29 elongation   Severe
  c.4539+172\>​​​​​​T   r.=                                                                                       p.(=)                                                                   None                       N.A.
  c.5461−1389C\>A       r.=                                                                                       p.(=)                                                                   None                       N.A.
  c.6148−471C\>T        r.=                                                                                       p.(=)                                                                   None                       N.A.

*Note:* The RNA and protein effect annotations show the most abundant product followed by the less abundant RNA product observed.

Abbreviations: N. A., not applicable; nt, nucleotide; PE, pseudoexon.

The equal sign depicts the presence of \>15% WT RNAs.

John Wiley & Sons, Ltd.

Of the six variants that showed no effect on splicing, the c.768+358C\>T, c.769−1778T\>C, and c.5461--1389C\>A variants showed alternative ESEs being recognized in the corresponding mutant and the c.2160+584A\>G, c.4539+1729G\>T, and c.6148−471C\>T variants significantly increased the splicing scores in different algorithms (Table S3). However, none of these six variants showed splicing defects in HEK293T cells in the in vitro assay (Figure S1).

3.3. Clinical characteristics of STGD1 cases carrying causal NCSS or deep‐intronic variants {#humu23890-sec-0100}
-------------------------------------------------------------------------------------------

Clinical data were collected from the corresponding patients carrying the variants assessed in this study. The overview of the *ABCA4* variants observed in trans in these patients as well as phenotypic details are provided in Tables S1 and S2, respectively.

For all variants assessed in this study, we quantified visible fragments from gel electrophoresis analysis to determine the severity of variants. The quantifications observed ≤15% of WT mRNA in four of five variants with visible WT fragments suggesting that they represent severe variants (Table S7). For the analysis of c.161G\>A, we noted naturally occurring exon skipping for exon 3 in 14% of the WT construct. Therefore, we normalized the full‐length fragment in mutant construct (44%) to the full‐length RNA including exon 3 in the WT (86%). The splice defect of c.161G\>A was classified as moderately severe due to the resulting 51% (86/44 × 100) remaining product. However, already earlier the missense variant was proposed to be severe in STGD1 cases, and therefore we argue that both the exon skipping and missense mutation are contributing to the severity of this variant. Six other variants did not show any WT fragments besides the mutant fragment and are therefore deemed severe causal variants. Variant c.3608−7G\>A did not show a splice defect and is therefore likely not causative until proven otherwise with another experimental setup.

Through this study, we established the splice defects for 12 *ABCA4* variants found in 12 macular dystrophy probands. The c.1938−619A\>G variant is located at position +5 of the PE and strengthened a cryptic SDS which likely led to the recognition of ESE SC35 and SRp55 motifs. These ESEs are located in the exon--intron boundaries and are shown to promote the recognition of exons with weak 5′ and 3′ splice sites and are being involved in exon definition by assisting in the recruitment of splicing factors before the removal of the adjacent introns. Therefore, the recognition of these ESE motifs will facilitate the splicing machinery to detect the nearby sequence as an exon (Buvoli, Buvoli, & Leinwand, [2007](#humu23890-bib-0008){ref-type="ref"}; Lam & Hertel, [2002](#humu23890-bib-0025){ref-type="ref"}; Wu, Zhang, & Zhang, [2005](#humu23890-bib-0047){ref-type="ref"}). The individual carrying this variant was identified with c.5882G\>A (p.Gly1961Glu) as a second variant and was shown to segregate with the disease in the family with a typical STGD1 phenotype (Zernant et al., [2014](#humu23890-bib-0050){ref-type="ref"}).

The c.2919−826T\>A variant is located at the penultimate nt of the newly recognized PE, increasing the SDS scores at the c.2919−824 positions. The corresponding patient carries the mild c.5882G\>A (p.(Gly1961Glu)) variant on the other allele and shows bull\'s eye maculopathy, which is characteristic for STGD1 cases carrying p.(Gly1961Glu) (Zernant et al., [2014](#humu23890-bib-0050){ref-type="ref"}).

4. DISCUSSION {#humu23890-sec-0110}
=============

We found splice defects for 12 of the 19 (63%) assessed NCSS or deep‐intronic *ABCA4* variants (Figure S2). Based on the midigene splice assays, 11 could be classified as severe variants and one variant (c.161G\>A) is considered to have a moderately severe splice effect. The splicing effects of all tested variants and their RNA and protein annotations were uploaded into the *ABCA4* Leiden Open (source) Variant Database (*ABCA4*‐LOVD). In addition, we updated the protein outcome for those variants that were already present in the database (<http://www.lovd.nl/ABCA4>).

Among nine NCSS variants, six variants were found to cause skipping of one or two exons. The c.5715−5T\>G variant revealed multiple fragments due to the splice defect. All erroneous fragments showed a 5′ elongation of exon 41, however, the variant also leads to skipping of both exon 39 and 40 and of exon 39 only. Whereas most NCSS variants lead to complete exon skipping, the midigene splice assays for both c.1937+5G\>A and c.6385A\>G variants resulted in partial exon deletions due to the use of cryptic splice sites within exons 13 and 46, respectively. As observed for c.1937+5G\>A, an upstream cryptic SDS at c.1806 was utilized which led to an in‐frame 132‐nt deletion of exon 13, thereby removing amino acid residues 603--646. This affects the first extracellular domain of the *ABCA4* protein, but a residual function of the protein cannot be excluded.

The prediction for the coding variant c.6385A\>G was challenging as the canonical SDS of exon 46 contains GC instead of GT, which is recognized only by the SSFL algorithm. The SSFL values were reduced from 91.8% to 80.3% for the mutant variant. While we anticipated a 26‐nt exon elongation due to high predicted scores for a cryptic splice site, or intron retention due to the small intron 46 size (73 nt), we observed the use of an upstream cryptic SDS at position c.6340. This resulted in a 47‐nt deletion of exon 46, leading to a frameshift resulting in a predicted truncated protein. We hypothesize that the strong cryptic SDS at position c.6386+27 (SSFL score: 85.3) may not be used by the splicing machinery due to the high abundance of silencers preventing the binding of splicing factors (Figure S3). The preferred cryptic SDS within the exon has a relatively low SSFL score of 67.7, but the region has few predicted silencer motifs and therefore likely is preferred over other SDSs. The corresponding patient with a retinitis pigmentosa‐like phenotype has the c.5461−10T\>C (p.\[Thr1821Aspfs\*6,Thr1821Valfs\*13\]) pathogenic variant as the other allele (Braun et al., [2013](#humu23890-bib-0006){ref-type="ref"}), which is the most frequent severe variant in *ABCA4* (Sangermano et al., [2016](#humu23890-bib-0034){ref-type="ref"}).

Among the 10 NEAR splice and deep‐intronic variants evaluated, c.1938−619A\>G, c.2919−826T\>A, and c.3050+370C\>T generated PEs that contain stop codons and thus result in predicted truncated ABCA4 proteins. Vaz‐Drago et al. ([2017](#humu23890-bib-0045){ref-type="ref"}) recently showed that the majority of deep‐intronic variants generate a canonical SAS or SDS, while the minority creates or disrupts an ESE or ESS element. In our study, only one (c.3050+370C\>T) out of three variants introduced a new splice site leading to a PE. Analysis of the c.1938−619A\>G variant revealed a complex effect and introduced two PEs. The variant created a 134‐nt PE as well as a second PE of 174 nt which resided 491 nt downstream. The 134‐nt PE was previously shown to result from the c.1937+435C\>G (Sangermano et al., [2019](#humu23890-bib-0035){ref-type="ref"}). To our knowledge, the phenomenon of two PEs generated by a single variant has not been described before and the underlying mechanism remains to be elucidated.

The WT c.3050+370C residue is part of a cryptic "GC‐type" splice site as predicted by SSFL (SSFL score: 78.9%), but apparently is not employed by the splicing machinery. The c.3050+370C\>T variant, however, creates a canonical GT (SSFL score: 81.8%) which was recognized by all five splice site algorithms and led as expected to a PE insertion that contains a premature stop codon after four amino acids p.(Leu1018Glufs\*4).

Six deep‐intronic variants did not show a splicing effect, while there were strong predictions for cryptic SDSs for the c.2160+584A\>G and c.4539−1729G\>T variants. An explanation for the absence of PEs may be a paucity of retina‐specific splicing motifs and/or an abundance of silencer motifs (Murphy, Cieply, Carstens, Ramamurthy, & Stoilov, [2016](#humu23890-bib-0029){ref-type="ref"}). Variants showing no effect on splicing in this study may still be proven to be pathogenic when assessed in induced Pluripotent Stem Cell (iPSC)‐derived photoreceptor precursors. For example, pathogenicity was proven when studying *ABCA4* variants c.4539+2001G\>A and c.4539+2028C\>T in photoreceptor precursor cells derived from patient fibroblasts while no effect on splicing was detected in fibroblasts of the same patients (Albert et al., [2018](#humu23890-bib-0002){ref-type="ref"}). Moreover, a retina‐specific increase of a 128‐nt PE insertion was also observed for the most frequent Leber congenital amaurosis‐associated *CEP290* variant, c.2991+1655A\>G (den Hollander et al., [2006](#humu23890-bib-0015){ref-type="ref"}; Dulla et al., [2018](#humu23890-bib-0017){ref-type="ref"}).

As current estimates indicate that NCSS, NEAR splice, and deep‐intronic variants represent 15--20% of the causes of recessive human diseases (Carss et al., [2017](#humu23890-bib-0009){ref-type="ref"}; Matlin, Clark, & Smith, [2005](#humu23890-bib-0027){ref-type="ref"}), we sought to assess pathogenicity of 19 *ABCA4* variants that were previously published, or identified in our cohort. We clearly determined the effect on splicing and, consequently, the highly likely pathogenicity for six NCSS variants as well as three deep‐intronic variants, and thereby contribute to a growing list of NCSS variants and the 16 pathogenic deep‐intronic variants published previously (Figure [4](#humu23890-fig-0004){ref-type="fig"}; Albert et al., [2018](#humu23890-bib-0002){ref-type="ref"}; Bauwens et al., [2019](#humu23890-bib-0004){ref-type="ref"}; Braun et al., [2013](#humu23890-bib-0006){ref-type="ref"}; Sangermano et al., [2019](#humu23890-bib-0035){ref-type="ref"}). Moreover, our study revealed a fourth NEAR splicing variant to be pathogenic in addition to the three previously described NEAR splice variants in *ABCA4* (Bauwens et al., [2019](#humu23890-bib-0004){ref-type="ref"}; Sangermano et al., [2018](#humu23890-bib-0036){ref-type="ref"}). An overview of the currently known pathogenic deep‐intronic and NEAR splice variants is presented in Figure [4](#humu23890-fig-0004){ref-type="fig"}.

![The landscape of all currently known pathogenic deep‐intronic and NEAR splicing variants in *ABCA4*. The three deep‐intronic variants and one NEAR splicing variant deemed as pathogenic in this study are depicted in red/italic. Other variants were described elsewhere (Albert et al., [2018](#humu23890-bib-0002){ref-type="ref"}; Bauwens et al., [2019](#humu23890-bib-0004){ref-type="ref"}; Braun et al., [2013](#humu23890-bib-0006){ref-type="ref"}; Sangermano et al., [2019](#humu23890-bib-0035){ref-type="ref"}). *ABCA4*, ATP‐binding cassette subfamily A member 4; NEAR, near exon aberrant RNA](HUMU-40-2365-g005){#humu23890-fig-0004}

Determining the precise effects of splice site variants will open new opportunities for therapeutic approaches for patients carrying these variants. As previously shown, modulation of *ABCA4* pre‐mRNA splicing can be executed through antisense oligonucleotides, which can bind complementarily to mRNA and manipulate the splicing process by skipping PEs (Albert et al., [2018](#humu23890-bib-0002){ref-type="ref"}; Bauwens et al., [2019](#humu23890-bib-0004){ref-type="ref"}; Sangermano et al., [2019](#humu23890-bib-0035){ref-type="ref"}). Moreover, antisense oligonucleotides have proven their effect in in vitro and in vivo studies for the most frequent deep‐intronic variant in *CEP290* that causes Leber congenital amaurosis (Collin et al., [2012](#humu23890-bib-0012){ref-type="ref"}; Garanto et al., [2016](#humu23890-bib-0023){ref-type="ref"}). The latter is currently in Phase II clinical trial (<https://clinicaltrials.gov/ct2/show/NCT03140969>).

By evaluating the pathogenic effects of putative splicing variants, we gained crucial knowledge for evaluation of yet to be identified NCSS, NEAR or deep‐intronic variants. While predictions by splice site algorithms are crucial, we also observed an important, and possibly essential, role of ESE and ESS motifs. Future studies regarding retina‐specific splicing motifs and proteins will improve predictions for the effect of novel NCSS and deep‐intronic variants in *ABCA4* as well as in other IRD‐associated genes.
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